Assessment of the radiation absorbed dose produced by 177Lu-iPSMA, 225Ac-iPSMA and 223RaCl2 to prostate cancer cell nuclei in a bone microenvironment model
- PMID: 30753987
- DOI: 10.1016/j.apradiso.2019.01.020
Assessment of the radiation absorbed dose produced by 177Lu-iPSMA, 225Ac-iPSMA and 223RaCl2 to prostate cancer cell nuclei in a bone microenvironment model
Abstract
This research aimed to assess the radiation absorbed dose produced by 177Lu-iPSMA (177Lu-prostate specific membrane antigen inhibitor), 225Ac-iPSMA and 223RaCl2 to prostate cancer cell nuclei in a simplified model of bone by using an experimental in-vitro prostate cancer LNCaP cell biokinetic study and Monte Carlo simulation with the MCNPX code. Results showed that 225Ac-iPSMA releases a nine hundred-fold radiation dose greater than 177Lu-iPSMA and 14 times more than 223RaCl2 per unit of activity retained in bone. 225Ac-iPSMA could be the best option for treatment of bone metastases in prostate cancer.
Keywords: Actinium-225; Lutetium-177; PSMA inhibitors; Prostate cancer; Theranostic radiopharmaceuticals.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Comparison between 177Lu-iPSMA and 225Ac-iPSMA dosimetry at a cellular level in an animal bone metastasis model.Appl Radiat Isot. 2021 Oct;176:109898. doi: 10.1016/j.apradiso.2021.109898. Epub 2021 Aug 14. Appl Radiat Isot. 2021. PMID: 34418726
-
177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: Biokinetics, Dosimetry, and Evaluation in Patients with Advanced Prostate Cancer.Contrast Media Mol Imaging. 2018 Nov 11;2018:5247153. doi: 10.1155/2018/5247153. eCollection 2018. Contrast Media Mol Imaging. 2018. PMID: 30534027 Free PMC article.
-
Effect of 177Lu-iPSMA on viability and DNA damage of human glioma cells subjected to hypoxia-mimetic conditions.Appl Radiat Isot. 2019 Apr;146:24-28. doi: 10.1016/j.apradiso.2019.01.021. Epub 2019 Jan 28. Appl Radiat Isot. 2019. PMID: 30743222
-
Alpha and Beta Radiation for Theragnostics.PET Clin. 2024 Jul;19(3):307-323. doi: 10.1016/j.cpet.2024.03.006. Epub 2024 Apr 29. PET Clin. 2024. PMID: 38688775 Review.
-
Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis.Curr Opin Urol. 2025 Jul 1;35(4):472-480. doi: 10.1097/MOU.0000000000001300. Epub 2025 May 5. Curr Opin Urol. 2025. PMID: 40325961
Cited by
-
Radiolabeled Peptides and Antibodies in Medicine.Bioconjug Chem. 2021 Jan 20;32(1):25-42. doi: 10.1021/acs.bioconjchem.0c00617. Epub 2020 Dec 16. Bioconjug Chem. 2021. PMID: 33325685 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous